Navigation Links
Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
Date:10/20/2009

BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research. The pooling process combines primary cells from multiple donors to create large lots with targeted activity levels. The resulting LiverPool product is flexible, customizable and repeatable, enabling scientists to run multiple studies on various compounds or NCEs anywhere in the world, and at any time, which speeds up decision making and reduces the time and cost of drug research.

"Our LiverPool product is a great example of Celsis IVT's pioneering work in developing ADME-Tox products that meet the research needs of our customers, while helping to take costs out of the drug discovery process," said Judy Madden, vice president of strategic development for Celsis. "We're proud that the US Patent Office has recognized our continued innovation and awarded us this patent."

Celsis IVT has been producing LiverPool products for more than five years and they have been incorporated into the standard research protocols of major pharmaceutical companies around the world. Research conducted with LiverPool has documented its efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. Scientific posters and LiverPool product information are available online at www.celsis.com/liverpool.

About Celsis IVT

Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit www.celsis.com/ivt for more information.

About Celsis International

Chicago-based Celsis International is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit www.celsis.com.

SOURCE Celsis International


'/>"/>
SOURCE Celsis International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chicago-Based Celsis International Goes Private
2. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
3. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
4. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
5. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. Peripheral Artery Disease (PAD) Patent Granted to Dimera
8. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
9. Delcath Systems Granted Third Orphan Drug Designation
10. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
11. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... 2017 , ... At its national board meeting in North Carolina, ARCS® ... Departments of Physics and Astronomy, has been selected for membership in ARCS Alumni ... the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding into ... a broad range of contract analysis services for advanced applications. Services will ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network ... at their fourth annual Conference where founders, investors, innovative practitioners and collaborators are ... pitch competition showcasing early stage digital health and med tech companies. , This ...
(Date:10/5/2017)... ... October 05, 2017 , ... Understanding the microbiome, the millions of ... health. Gut Love: You Are My Future, the newest exhibit on display at the ... explores the human condition through the lens of the gut microbiome. , Gut ...
Breaking Biology Technology:
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):